← Leaderboards
Thomas C Chen
University Of Southern California
$2,031,783
Attributed
$2,836,314
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2013–25$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,836,314 · 8
By mechanism
R41$1,637,385 · 5
R42$1,007,612 · 1
M01$191,317 · 2
Top collaborators
- Weijun Wang2 shared
- Florence M Hofman1 shared
- Radu Minea1 shared
Most similar at University Of Southern California
Same institution · by research overlap
- Austin Mircheff$2,076,459
- Radu Minea$892,109
Others in their field
Top investigators on “Neoplasm /Cancer Chemotherapy”
- Charles A Coltman · Southwest Oncology Group$171,655,324
- Norman Wolmark · Nsabp Foundation, Inc.$63,095,441
- Philip J Disaia · University Of California Irvine$41,530,194
- Walter J Curran · Thomas Jefferson University$37,520,030
- Samuel A Wells · Duke University$32,148,803
- Gregory H Reaman · National Childhood Cancer Foundation$19,436,422
Research focus
Neoplasm /Cancer ChemotherapyHuman Therapy EvaluationHuman SubjectAntineoplasticsClinical ResearchAstrocytomaTumorTemozolomideQuality Of LifeClinical TrialsMalignant Neoplasm Of BrainBlood - Brain Barrier AnatomyBrainIn VitroResistancePerilla AlcoholNeoplastic CellPharmaceutical PreparationsMedicalGlioblastomaOralPenetrationBone MarrowMonoterpenes
Grant awards (14)
Developing a Clinically Relevant Radiosensitizer for Temozolomide-resistant Gliomas$1,007,612
R42 · FY2025 · CA · contact PI
Development of NEO212, A Novel Oral Drug for the Treatment of Acute Myeloid Leukemia$399,998
R41 · FY2025 · CA · contact PI
Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas$336,000
R41 · FY2020 · CA · contact PI
Innovative Nose-to-Brain Anticancer Drug Transport Facilitated by NEO100$1,450
R41 · FY2019 · CA · contact PI
Innovative Nose-to-Brain Anticancer Drug Transport Facilitated by NEO100$300,000
R41 · FY2018 · CA · contact PI
Temozolomide Perillyl Alcohol Conjugate as Treatment for Recurrent Malignant Brain tumors$300,000
R41 · FY2016 · CA · contact PI
A Novel Brachytherapy Agent for GBM$299,937
R41 · FY2013 · CA · contact PI
SU 101 VERSUS PROCARBAZINE FOR PATIENTS W/ GLIOBLASTOMA$0
M01 · FY2002 · RR
SU 101 VERSUS PROCARBAZINE FOR PATIENTS W/ GLIOBLASTOMA$155,764
M01 · FY2001 · RR
SU 101 VERSUS PROCARBAZINE FOR PATIENTS W/ GLIOBLASTOMA$0
M01 · FY2001 · RR
SU 101 VERSUS PROCARBAZINE FOR PATIENTS W/ GLIOBLASTOMA$35,553
M01 · FY2000 · RR
SU101 FOR PATIENTS WITH ANAPLASTIC ASTROCYTOMA RELAPSE$0
M01 · FY2000 · RR
SU101 FOR PATIENTS WITH ANAPLASTIC ASTROCYTOMA RELAPSE$0
M01 · FY2000 · RR
SU 101 VERSUS PROCARBAZINE FOR PATIENTS W/ GLIOBLASTOMA$0
M01 · FY2000 · RR